Appia Bio

Biotech · Private

Engineered allogeneic natural killer (NK) cell therapy for hematologic malignancies

appiabio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
9
0 granted · 9 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3118PROTERIS BIOTECH, INC.——
3119MEDITATI INC.——
3120BIOPICO SYSTEMS Inc.——
3121Appia Bio——
3122Nami Therapeutics Corp.——
3123Silicon Insite, Inc.——
3124OncoSolutions LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 9
  • Highly Efficient And Scalable Production Of Engineered T Cells From Stem Cellsapplication
  • Highly Efficient And Scalable Production Of Engineered T Cells From Stem Cellsapplication
  • Highly Efficient And Scalable Production Of Engineered T Cells From Stem Cellsapplication
  • Engineering Stem Cell T Cells With Multiple T Cell Receptorsapplication
  • Production Of Engineered T Cells From Stem Cellsapplication
  • Engineering Stem Cells For Allogenic Car T Cell Therapiesapplication
  • Engineering Stem Cell T Cells With Mulitple T Cell Receptorsapplication
  • Engineering Stem Cells For Allogenic Car T Cell Therapiesapplication
  • Production Of Engineered T Cells From Stem Cellsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.